Previous Close | 8.09 |
Open | 8.27 |
Bid | 8.71 x 900 |
Ask | 9.29 x 800 |
Day's Range | 8.27 - 8.83 |
52 Week Range | 7.73 - 24.90 |
Volume | |
Avg. Volume | 155,467 |
Market Cap | 389.43M |
Beta (5Y Monthly) | 1.82 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.97 |
Earnings Date | Aug 09, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.57 |
Subscribe to Yahoo Finance Plus to view Fair Value for MGTX
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -42.86% and 39.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Patients- Phase 1 AQUAx Study of AAV-hAQP1 for Radiation-Induced Xerostomia Completed Dosing of Both Unilateral and Bilateral Cohorts in the First Quarter of 2022 LONDON and NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results fo
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...